Skip to content
Log in
Sponsored AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI
Open access

Restoring Parkin Function: An AAV Gene Therapy Approach for Early-Onset Parkinson’s Disease

S. Basu Tyler G. Demarest Nicholas J. Gattone A. Gilsrud Brittany Wicks A. Khatiwada Mohammad Nayal R. Gentzel D. Cohen E. Kostuk Derek P. Narendra P. Gonzalez-Alegre M. Biferi Elizabeth Ramsburg
Jul 2026 · bioRxiv · 0 citations
Biology Medicine

TL;DR

The results support the potential of AAV-Parkin gene therapy as a disease-modifying approach for Parkin-deficient EOPD and developed a translatable gene therapy approach using rodents.

DOI PubMed Semantic Scholar
Read PDF

Similar papers

Open access Jul 2026

Dissecting the transcriptome of Parkin (PRKN)-linked Parkinson’s disease using 2D and 3D hiPSC-neuronal models

This work generates human induced pluripotent stem cell-derived midbrain dopaminergic neurons using both a 2D differentiation protocol and a recently developed 3D method based on the microencapsulation of hiPSCs in small alginate/fibronectin beads.

A. Zanon, E. Kerschbamer, D. Riekschnitz et al. · 0 citations
Open access Aug 2026

Therapeutic potential of the Nrf2 activator omaveloxolone in spinocerebellar ataxia type 3 in cellular and Drosophila models

Findings support the protective potential of RTA-408 in SCA3-related models and show its effects were associated with activation of Nrf2-related antioxidant responses, p62 upregulation, and selected improvements in mitochondrial phenotypes.

Shin-Hung Pan, Jui-Chih Chang, Wan-Hsuan Lin et al. · 0 citations
Jul 2026

AAV.hBAG3 Gene Therapy Improves Phenotype in a Valosin Containing Protein Mouse Model of Hereditary Inclusion Body Myositis

Evidence is presented that the strategy of supporting the ALP system by overexpressing BAG3 has potential therapeutic use for myodegenerative conditions associated with abnormal protein aggregates and mitochondrial turnover.

B. Ozes, Ling-Ying Tong, M. Myers et al. · 0 citations
Open access Jul 2026

BL-918 as a Novel Neuroprotective Agent Targeting SMP30 in Parkinson’s Disease: A Therapeutic Evaluation

It is suggested that BL-918 could potentially modulate SMP30 at the functional protein level, and SwissADME and ProTox 3.0 characterized BL-918 as a viable therapeutic lead, outlining key pharmacokinetic targets for future optimization.

Hardi M. Makwana, S. S. Swain, B. Paital et al. · 0 citations
Open access Aug 2026

SNCA-targeted transcriptional repression therapy alleviates pathological and behavioral perturbations in a Parkinson's disease mouse model

In vivo proof-of-concept for SNCA-targeted transcriptional repression therapy in a PD-mouse model is provided and its further preclinical development toward investigational new drug enablement is supported.

Bernadette O'Donovan, Joseph E. Rittiner, Suraj Upadhya et al. · 0 citations
Aug 2026

Physiologically Regulated Frataxin Gene Replacement Restores Neurological Function in a Mouse Model of Friedreich Ataxia.

It is demonstrated that physiologically regulated FXN replacement is sufficient to achieve substantial functional rescue in FA, supporting a gene therapy strategy based on a transgene expression driven by endogenous regulatory elements.

Federica Pilotto, Laure Dall'Agnol, L. Reutenauer et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.